Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corp (NY: CVM )

1.500 -0.020 (-1.32%)
Official Closing Price Updated: 8:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 133,523
Open 1.540
Bid (Size) 1.500 (3)
Ask (Size) 1.680 (1)
Prev. Close 1.520
Today's Range 1.500 - 1.600
52wk Range 1.040 - 3.230
Shares Outstanding 50,104,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire

Performance

YTD
-44.24%
-44.24%
1 Month
-26.83%
-26.83%
3 Month
-38.27%
-38.27%
6 Month
+33.93%
+33.93%
1 Year
-39.02%
-39.02%

More News

Read More
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
Why CEL-SCI Corporation (CVM) Shares Are Diving
Via Benzinga
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023
Via InvestorPlace
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
Via Investor Brand Network
Exposures Product Safety
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
From CEL-SCI Corporation
Via Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
Via Benzinga
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
Via FinancialNewsMedia
Exposures Product Safety
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
From CEL-SCI Corporation
Via Business Wire
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.